S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NYSE:ENFN

Enfusion (ENFN) Stock Price, News & Analysis

$9.25
+0.02 (+0.22%)
(As of 04:37 PM ET)
Today's Range
$9.19
$9.35
50-Day Range
$7.78
$9.57
52-Week Range
$7.37
$11.56
Volume
336,283 shs
Average Volume
412,319 shs
Market Capitalization
$1.18 billion
P/E Ratio
115.64
Dividend Yield
N/A
Price Target
$9.33

Enfusion MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
0.9% Upside
$9.33 Price Target
Short Interest
Bearish
6.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Enfusion in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$54,849 Sold Last Quarter
Proj. Earnings Growth
142.86%
From $0.07 to $0.17 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.07 out of 5 stars

Computer And Technology Sector

494th out of 587 stocks

Prepackaged Software Industry

179th out of 198 stocks

ENFN stock logo

About Enfusion Stock (NYSE:ENFN)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Stock Price History

ENFN Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Analysts Set Enfusion, Inc. (NYSE:ENFN) PT at $9.33
Stifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)
How you can target big results without spending big money!
While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades!
William Blair Reaffirms Their Buy Rating on Enfusion (ENFN)
Earnings Outlook For Enfusion
Goldman Sachs Downgrades Enfusion (ENFN)
Enfusion to Host Investor Day on March 19, 2024
Enfusion downgraded to Underweight on client risks at JPMorgan
JP Morgan Downgrades Enfusion: Here's What You Need To Know
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.33
High Stock Price Target
$11.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+0.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$6.03 million
Pretax Margin
6.58%

Debt

Sales & Book Value

Annual Sales
$174.54 million
Cash Flow
$0.15 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
77,892,000
Market Cap
$1.18 billion
Optionable
Optionable
Beta
0.99
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Oleg Movchan (Age 49)
    CEO & Director
    Comp: $876.34k
  • Mr. Bradley Herring (Age 53)
    Chief Financial Officer
    Comp: $267.05k
  • Ms. Bronwen Bastone (Age 51)
    Chief People Officer
    Comp: $566.25k
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Neal Pawar
    Chief Operating Officer
  • Ms. Valeria Gutowski (Age 42)
    Chief Accounting Officer
  • Mr. Ignatius Tochukwu Njoku
    Head of Investor Relations
  • Matt Campobasso
    General Counsel
  • Mr. Joseph Defeo
    Global Head of Managed Services Production
  • Mr. Jeff Young
    Head of Implementation

ENFN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ENFN shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price target for 2024?

6 Wall Street analysts have issued 12 month price targets for Enfusion's stock. Their ENFN share price targets range from $8.00 to $11.00. On average, they predict the company's share price to reach $9.33 in the next year. This suggests a possible upside of 0.9% from the stock's current price.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2024?

Enfusion's stock was trading at $9.70 at the beginning of the year. Since then, ENFN stock has decreased by 4.6% and is now trading at $9.25.
View the best growth stocks for 2024 here
.

Are investors shorting Enfusion?

Enfusion saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,020,000 shares, an increase of 80.8% from the February 29th total of 1,670,000 shares. Based on an average trading volume of 395,300 shares, the days-to-cover ratio is presently 7.6 days. Currently, 6.7% of the company's shares are sold short.
View Enfusion's Short Interest
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ENFN earnings forecast
.

What guidance has Enfusion issued on next quarter's earnings?

Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million.

When did Enfusion IPO?

Enfusion (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Enfusion's stock is owned by a variety of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (9.27%), Vanguard Group Inc. (2.83%), Vanguard Group Inc. (2.83%), Wellington Management Group LLP (0.38%), Northern Trust Corp (0.27%) and Charles Schwab Investment Management Inc. (0.23%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski.
View institutional ownership trends
.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENFN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners